vs
ALBANY INTERNATIONAL CORP（AIN）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
ALBANY INTERNATIONAL CORP的季度营收约是Orthofix Medical Inc.的1.5倍（$321.2M vs $219.9M），ALBANY INTERNATIONAL CORP净利率更高（4.3% vs -1.0%，领先5.3%），ALBANY INTERNATIONAL CORP同比增速更快（12.0% vs 2.0%），ALBANY INTERNATIONAL CORP自由现金流更多（$51.4M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 1.2%）
奥尔巴尼国际是全球先进材料与工业技术企业，下设两大核心业务板块：为造纸等工业生产提供定制工程织物的机械织物部门，以及为航空航天、国防领域研发高性能复合材料部件的工程复合材料部门，业务覆盖全球多个区域。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
AIN vs OFIX — 直观对比
营收规模更大
AIN
是对方的1.5倍
$219.9M
营收增速更快
AIN
高出10.0%
2.0%
净利率更高
AIN
高出5.3%
-1.0%
自由现金流更多
AIN
多$34.6M
$16.8M
两年增速更快
OFIX
近两年复合增速
1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $321.2M | $219.9M |
| 净利润 | $13.9M | $-2.2M |
| 毛利率 | 31.1% | 71.1% |
| 营业利润率 | 9.3% | 0.2% |
| 净利率 | 4.3% | -1.0% |
| 营收同比 | 12.0% | 2.0% |
| 净利润同比 | -21.5% | 92.4% |
| 每股收益（稀释后） | $0.56 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AINOFIX
| Q4 25 | $321.2M | $219.9M | ||
| Q3 25 | $261.4M | $205.6M | ||
| Q2 25 | $311.4M | $203.1M | ||
| Q1 25 | $288.8M | $193.6M | ||
| Q4 24 | $286.9M | $215.7M | ||
| Q3 24 | $298.4M | $196.6M | ||
| Q2 24 | $332.0M | $198.6M | ||
| Q1 24 | $313.3M | $188.6M |
净利润AINOFIX
| Q4 25 | $13.9M | $-2.2M | ||
| Q3 25 | $-97.8M | $-22.8M | ||
| Q2 25 | $9.2M | $-14.1M | ||
| Q1 25 | $17.4M | $-53.1M | ||
| Q4 24 | $17.7M | $-29.1M | ||
| Q3 24 | $18.0M | $-27.4M | ||
| Q2 24 | $24.6M | $-33.4M | ||
| Q1 24 | $27.3M | $-36.0M |
毛利率AINOFIX
| Q4 25 | 31.1% | 71.1% | ||
| Q3 25 | -19.1% | 72.2% | ||
| Q2 25 | 31.3% | 68.7% | ||
| Q1 25 | 33.4% | 62.8% | ||
| Q4 24 | 31.5% | 69.0% | ||
| Q3 24 | 30.3% | 68.7% | ||
| Q2 24 | 33.9% | 67.8% | ||
| Q1 24 | 34.7% | 67.5% |
营业利润率AINOFIX
| Q4 25 | 9.3% | 0.2% | ||
| Q3 25 | -44.6% | -8.3% | ||
| Q2 25 | 7.2% | -7.9% | ||
| Q1 25 | 9.8% | -25.2% | ||
| Q4 24 | 8.5% | -5.3% | ||
| Q3 24 | 8.4% | -9.6% | ||
| Q2 24 | 12.9% | -12.5% | ||
| Q1 24 | 12.4% | -15.6% |
净利率AINOFIX
| Q4 25 | 4.3% | -1.0% | ||
| Q3 25 | -37.4% | -11.1% | ||
| Q2 25 | 2.9% | -6.9% | ||
| Q1 25 | 6.0% | -27.4% | ||
| Q4 24 | 6.2% | -13.5% | ||
| Q3 24 | 6.0% | -13.9% | ||
| Q2 24 | 7.4% | -16.8% | ||
| Q1 24 | 8.7% | -19.1% |
每股收益（稀释后）AINOFIX
| Q4 25 | $0.56 | $-0.05 | ||
| Q3 25 | $-3.37 | $-0.57 | ||
| Q2 25 | $0.31 | $-0.36 | ||
| Q1 25 | $0.56 | $-1.35 | ||
| Q4 24 | $0.57 | $-0.76 | ||
| Q3 24 | $0.57 | $-0.71 | ||
| Q2 24 | $0.79 | $-0.88 | ||
| Q1 24 | $0.87 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $112.3M | $82.0M |
| 总债务越低越好 | $455.7M | — |
| 股东权益账面价值 | $726.2M | $450.0M |
| 总资产 | $1.7B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.63× | — |
8季度趋势，按日历期对齐
现金及短期投资AINOFIX
| Q4 25 | $112.3M | $82.0M | ||
| Q3 25 | $108.3M | $62.9M | ||
| Q2 25 | $106.7M | $65.6M | ||
| Q1 25 | $119.4M | $58.0M | ||
| Q4 24 | $115.3M | $83.2M | ||
| Q3 24 | $127.2M | $30.1M | ||
| Q2 24 | $116.4M | $26.4M | ||
| Q1 24 | $125.4M | $27.0M |
总债务AINOFIX
| Q4 25 | $455.7M | — | ||
| Q3 25 | $480.6M | $157.2M | ||
| Q2 25 | $444.7M | $157.0M | ||
| Q1 25 | $416.4M | $156.9M | ||
| Q4 24 | $318.5M | $157.0M | ||
| Q3 24 | $362.2M | $118.5M | ||
| Q2 24 | $377.1M | $118.0M | ||
| Q1 24 | $439.1M | $118.2M |
股东权益AINOFIX
| Q4 25 | $726.2M | $450.0M | ||
| Q3 25 | $739.3M | $442.5M | ||
| Q2 25 | $888.6M | $458.3M | ||
| Q1 25 | $900.0M | $458.3M | ||
| Q4 24 | $943.5M | $503.1M | ||
| Q3 24 | $991.0M | $525.9M | ||
| Q2 24 | $967.5M | $546.0M | ||
| Q1 24 | $967.5M | $570.3M |
总资产AINOFIX
| Q4 25 | $1.7B | $850.6M | ||
| Q3 25 | $1.7B | $832.6M | ||
| Q2 25 | $1.7B | $837.2M | ||
| Q1 25 | $1.7B | $823.1M | ||
| Q4 24 | $1.6B | $893.3M | ||
| Q3 24 | $1.8B | $867.9M | ||
| Q2 24 | $1.8B | $882.0M | ||
| Q1 24 | $1.8B | $906.0M |
负债/权益比AINOFIX
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.65× | 0.36× | ||
| Q2 25 | 0.50× | 0.34× | ||
| Q1 25 | 0.46× | 0.34× | ||
| Q4 24 | 0.34× | 0.31× | ||
| Q3 24 | 0.37× | 0.23× | ||
| Q2 24 | 0.39× | 0.22× | ||
| Q1 24 | 0.45× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.7M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $51.4M | $16.8M |
| 自由现金流率自由现金流/营收 | 16.0% | 7.6% |
| 资本支出强度资本支出/营收 | 6.9% | 4.9% |
| 现金转化率经营现金流/净利润 | 5.31× | — |
| 过去12个月自由现金流最近4个季度 | $82.6M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流AINOFIX
| Q4 25 | $73.7M | $27.7M | ||
| Q3 25 | $43.9M | $12.4M | ||
| Q2 25 | $32.7M | $11.6M | ||
| Q1 25 | $2.1M | $-18.4M | ||
| Q4 24 | $78.5M | $23.7M | ||
| Q3 24 | $47.0M | $11.7M | ||
| Q2 24 | $83.4M | $9.0M | ||
| Q1 24 | $9.6M | $-18.6M |
自由现金流AINOFIX
| Q4 25 | $51.4M | $16.8M | ||
| Q3 25 | $25.9M | $2.5M | ||
| Q2 25 | $18.8M | $4.5M | ||
| Q1 25 | $-13.5M | $-25.1M | ||
| Q4 24 | $60.2M | $15.2M | ||
| Q3 24 | $31.6M | $6.3M | ||
| Q2 24 | $63.6M | $-360.0K | ||
| Q1 24 | $-17.3M | $-29.1M |
自由现金流率AINOFIX
| Q4 25 | 16.0% | 7.6% | ||
| Q3 25 | 9.9% | 1.2% | ||
| Q2 25 | 6.0% | 2.2% | ||
| Q1 25 | -4.7% | -13.0% | ||
| Q4 24 | 21.0% | 7.0% | ||
| Q3 24 | 10.6% | 3.2% | ||
| Q2 24 | 19.2% | -0.2% | ||
| Q1 24 | -5.5% | -15.4% |
资本支出强度AINOFIX
| Q4 25 | 6.9% | 4.9% | ||
| Q3 25 | 6.9% | 4.8% | ||
| Q2 25 | 4.5% | 3.5% | ||
| Q1 25 | 5.4% | 3.5% | ||
| Q4 24 | 6.4% | 4.0% | ||
| Q3 24 | 5.2% | 2.7% | ||
| Q2 24 | 6.0% | 4.7% | ||
| Q1 24 | 8.6% | 5.6% |
现金转化率AINOFIX
| Q4 25 | 5.31× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 4.44× | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 3.39× | — | ||
| Q1 24 | 0.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
